Oncology Central

The integration of locoregional with systemic adjuvant therapy for early-stage breast cancer: the shifting sands of decision-making

0

Given the generally excellent outcomes for modern breast cancer treatment, the recognition that overtreatment is commonplace is the driving force to reduce the treatment impact of surgery, radiation therapy and chemotherapy. Many recent trials have demonstrated that fewer axillary lymph node dissections, smaller radiation field sizes and less administration of chemotherapy are all feasible without compromising the long-term outcomes.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.